Advertisement

Search Results

Advertisement



Your search for all items matches 20271 pages

Showing 151 - 200


issues in oncology

2019 Quality Care: End-of-Life Care in Western Washington State vs Alberta, Canada

In a study to be presented by Khaki et al at the 2019 ASCO Quality Care Symposium, researchers found more aggressive end-of-life measures—including use of chemotherapy and admissions to the intensive care unit (ICU)—were employed in the last 30 days of life in Western Washington state vs Alberta,...

kidney cancer
immunotherapy

Individualized Axitinib Regimens After Immunotherapy for Advanced Renal Cell Carcinoma

In a phase II study reported in The Lancet Oncology, Ornstein et al found that individualized axitinib regimens showed activity in patients with locally recurrent or metastatic renal cell carcinoma who had previously received immune checkpoint inhibitor therapy, although the progression-free...

issues in oncology
cost of care

2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care

Drug costs and requirements for prior authorization of treatment plans pose barriers to cancer treatment and can potentially affect outcomes for many patients, according to two studies that will be presented at the ASCO Quality Care Symposium. The studies respectively examine how the high...

issues in oncology
lung cancer

2019 Quality Care: Clinical Trial Enrollment May Be Associated With Reduced Mortality in Patients With Metastatic Lung Cancer

Researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle investigated the relationship between participation in a clinical trial and overall survival in patients with advanced non–small cell lung cancer (NSCLC). Cristina Merkhofer, MD, MHS, will present...

prostate cancer

TITAN Trial: Apalutamide Adds to Options for Men With Metastatic Hormone-Sensitive Prostate Cancer

Androgen-deprivation therapy has been, and remains, the standard of care for patients with metastatic prostate cancer. Patients are often surprised to know that was all we would do to control their disease and sometimes asked why they would not get chemotherapy, as for other cancers. I would take...

prostate cancer

Addition of Apalutamide to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer

As reported in The New England Journal of Medicine by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the first analysis of the phase III TITAN trial has shown that the addition of apalutamide to androgen-deprivation therapy improved radiographic progression-free and...

issues in oncology

FDA Recommendation on Duodenoscopes With Disposable Components

The U.S. Food and Drug Administration (FDA) has recommended that duodenoscope manufacturers and health-care facilities transition to different types of duodenoscopes that may pose less risk to patient safety. Specifically, because of challenges with cleaning these devices for reuse and persistent...

issues in oncology

Analysis of HPV-Related Cancers Reported From 2012 to 2016

During 2012–2016, an average of approximately 34,800 human papillomavirus (HPV)-associated cancers were reported each year, according to a new study published by Senkomago et al in Morbidity and Mortality Weekly Report. Among the cancers probably caused by HPV, 92% are attributable to the HPV types ...

leukemia
survivorship

Risk of Infections in Survivors of Childhood Leukemia

In a study reported in the Journal of Clinical Oncology, Pelland-Marcotte et al found that survivors of childhood leukemia remained at significantly increased risk of infection compared with matched controls during an extended period following completion of treatment.   Study Details The...

hematologic malignancies
issues in oncology

Reducing Time to Chemotherapy Initiation in Patients Electively Admitted to a Hematologic Malignancy Service

In a single-institution study reported in the Journal of Oncology Practice, Galeas et al found that intervention in key drivers in the care process could reduce the time to initiation of chemotherapy in patients with elective admission to a hematologic malignancy service. Study Details The goal of...

supportive care
symptom management

Study Explores Efficacy of Lower-Dose Olanzapine in Combination With Standard Antiemetic Regimen

Olanzapine at a 5-mg dose, when combined with aprepitant, palonosetron, and dexamethasone, significantly reduced the risk of delayed nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to new research. The study investigators believe this approach may be considered a...

issues in oncology
survivorship

What Role Do Physicians Play in Health Promotion Among Patients With Cancer?

A recent study published by Stump et al in Cancer indicated that certain physicians who care for patients with cancer do not often promote healthy lifestyle changes to cancer survivors, and they may fear that providing such advice would distress or overwhelm patients. The findings are noteworthy...

hepatobiliary cancer
pancreatic cancer

Results From the TAPUR Study on Palbociclib for Pancreatic Cancer and Cholangiocarcinoma

New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study have demonstrated that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A-mutated or -deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma. These findings were...

immunotherapy

Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types

In a study reported in JAMA Oncology, Lee and Ruppin found that CD8-positive T-cell abundance, tumor mutational burden, and high PD1 gene expression were the strongest predictors of response to anti–programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment across cancer...

breast cancer

Pyrotinib or Lapatinib With Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

In a Chinese phase II trial reported in the Journal of Clinical Oncology by Ma et al, the combination of the pan-ErbB inhibitor pyrotinib and capecitabine improved response rate vs lapatinib/capecitabine in women with HER2-positive relapsed or metastatic breast cancer previously treated with...

genomics/genetics
leukemia

Chromosomal Abnormalities and Prognosis in NPM1-Mutant AML

In a study reported in the Journal of Clinical Oncology, Angenendt et al found that adverse-risk cytogenetics were associated with significantly poorer outcomes vs normal karyotype among patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation. As stated by the...

prostate cancer

Many Choices Now for Men With Metastatic Hormone-Sensitive Prostate Cancer: How to Decide?

Based on the recently published ENZAMET, ARCHES, and TITAN trials,1-3 we now have several choices of systemic combination therapies for men with metastatic hormone-sensitive prostate cancer; the ENZAMET trial is reviewed in this issue of The ASCO Post. In 2019, men are now faced with decisions of...

prostate cancer

Enzalutamide Improves Survival vs Standard First-Line Treatment in Hormone-Sensitive Metastatic Prostate Cancer

As reported in TheNew England Journal of Medicine by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health in Melbourne, and colleagues, the phase III ENZAMET trial has shown that the androgen receptor inhibitor enzalutamide improved progression-free and overall survival...

colorectal cancer
issues in oncology

Text Instructions and Reminders May Improve Colonoscopy Adherence Rates

Having text message conversations with patients 1 week before they are scheduled for a colonoscopy decreased “no-show” rates, according to a recent study published by Mahmud et al in Health Education & Behavior. Through sending reminders and instruction, the team increased the rate of...

head and neck cancer

Maura L. Gillison, MD, PhD, Pioneer in HPV-Related Head and Neck Cancer, Has Often Changed Lanes in Her Career

When The ASCO Post asked physician-scientist Maura L. Gillison, MD, PhD, where she was from, she answered, “North America.” Actually, she was born in Canada, but her father worked for a large international company, so the family moved regularly through Canada, the United States, and Mexico. “I...

issues in oncology

Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students

A growing number of middle and high school students are being exposed to secondhand aerosols from electronic cigarettes (e-cigarettes) by living with or being around individuals who are vaping, according to data from a national survey. Such exposure increased rapidly in 2018 compared to the years...

issues in oncology
survivorship

High-Deductible Health Plans, Access to Care, and Emergency Department Use Among Cancer Survivors

In a study reported in the Journal of Oncology Practice, Zheng et al found that patients with cancer and high-deductible health plans had increases in delayed/forgone care, an effect that was attenuated for those with health savings accounts. Emergency department use was similar across insurance...

survivorship
issues in oncology

Risks of Cardiovascular Diseases in Survivors of Adult Cancers

In a study reported in The Lancet, Strongman et al found that survivors of most site-specific cancers had an increased risk for one or more cardiovascular diseases during follow-up compared with a matched control group of patients without cancer. This population-based cohort study employed multiple ...

kidney cancer
immunotherapy

Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC

As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, extended follow-up of the phase III CheckMate 214 trial has shown a maintained survival benefit for first-line nivolumab/ipilimumab vs sunitinib in patients with previously untreated intermediate- or poor-risk advanced...

LEAD Conference to Focus on Empowering Women in Hematology/Oncology

Nearly 46% of medical school graduates are women, yet women physicians remain underrepresented in leadership roles. A recent report on The State of Women in Academic Medicine notes that women make up nearly 50% of medical school applicants, but only 21% of full professors, 16% of deans, and 15% of...

immunotherapy
skin cancer

Phase Ib Trial of Toripalimab/Axitinib in Asian Patients With Advanced Mucosal Melanoma

In a Chinese phase Ib study reported in the Journal of Clinical Oncology, Sheng et al reported activity with the combination of the anti–programmed cell death protein 1 (PD-1) agent toripalimab plus axitinib in patients with metastatic mucosal melanoma. As stated by the investigators, whereas...

hepatobiliary cancer

Direct-Acting Antiviral Therapy and Reduced Mortality in Patients With Hepatitis C and a History of Liver Cancer

A study published by Singal et al in Gastroenterology demonstrated that treatment with antiviral therapy for hepatitis C reduced liver-related deaths by nearly 50% in patients with a history of liver cancer. Previous Research The finding builds on a December 2018 study by Singal et al also...

pancreatic cancer

Role of the YAP Regulatory Network in Pancreatic Ductal Adenocarcinoma

Researchers have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma. They say their findings, published by Murakami et al in Developmental Cell, suggest that inhibiting the YAP biologic network may effectively regress early-stage...

breast cancer
issues in oncology

FDA Issues Draft Guidance Encouraging Inclusion of Male Patients in Breast Cancer Clinical Trials

A draft guidance issued by the U.S. Food Drug Administration (FDA) on August 26 includes draft recommendations for the inclusion of male patients in breast cancer clinical trials. Historically, males either have not been included in clinical trials for drugs to treat breast cancer, or inclusion of...

neuroendocrine tumors

Prognostic Tool for Advanced, Well-Differentiated Neuroendocrine Tumors Treated With a Somatostatin Analog

In the GETNE-TRASGU study (Spanish Group of Neuroendocrine and Endocrine Tumors Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) reported in the Journal of Clinical Oncology, Carmona-Bayonas et al developed a predictive model for progression-free survival in...

multiple myeloma

Selinexor/Dexamethasone in Triple-Class Refractory Multiple Myeloma

In the phase IIb STORM Part 2 study reported in The New England Journal of Medicine, Chari et al found that the combination of oral selinexor and dexamethasone produced responses in patients with multiple myeloma refractory to prior treatment with an alkylating agent, immunomodulatory agent, and...

solid tumors

FDA Clears Next-Generation Scalp-Cooling Device

ON JUNE 27, 2019, the U.S. Food and Drug Administration (FDA) granted clearance of the DigniCap Delta scalp-cooling system to Dignitana, for use by health-care providers in the United States. The device is a fourth generation of the DigniCap scalp-cooling system. It is indicated to reduce the...

kidney cancer
prostate cancer
immunotherapy

Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer

There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...

New From ASCO eLearning: Platform Offers Enhanced, Personalized Online Learning Experience

PERSONALIZATION AND STREAMLINED navigation were two priorities of the recent rebranding of ASCO University. Now known as ASCO eLearning (elearning.asco.org), the rebrand more accurately reflects what the program offers and who it is intended for. “The priority I see for ASCO eLearning is to make...

Spotlight on Women Who Conquer Cancer

WOMEN WHO CONQUER CANCER (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, funded 21 Young Investigator...

Your Stories: How to Become a Conqueror

NOT ALL PATIENTS face their cancer diagnosis with a conqueror’s sprit. In the podcast “How to Become a Conqueror,” Linda Zanetti shares how a community of support gave her the resources—and the will—to survive leukemia. Developed by Conquer Cancer®, the ASCO Foundation, the Your Stories podcast...

Newly Updated ASCO Answers Resource to Help Your Patients Quit Tobacco

THE ASCO ANSWERS Stopping Tobacco Use After a Cancer Diagnosis booklet offers people with cancer and their caregivers information on why and how to quit tobacco use. With information on available treatments and resources, the guide gives patients practical tools to work with their health-care team ...

20 Oncology Practices Achieve ASCO’s QOPI® Certification in Second Quarter of 2019

TWENTY PRACTICES in three countries elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the second quarter of this year. ASCO commends these practices that have demonstrated their commitment to providing the highest-quality oncology care to...

ASCO Breakthrough: Why Now, Why Bangkok?

ASCO Breakthrough: A Global Summit for Oncology Innovators was created, in part, to recognize our increasingly large and international community of members, to bring a meeting to their area, to go outside the United States, and shake up our own thinking. Why is now the time to organize a summit...

Some Practices May Not Be Subject to USP and Standards

ASCO recently received clarification from the United States Pharmacopeia (USP) around the newly revised USP General Chapter <797> Pharmaceutical Compounding Standards–Sterile Preparations and USP General Chapter <800> Hazardous Drugs–Handling in Health-Care Settings, which become...

Register for ASCO’s Research Community Forum 2019 Annual Meeting

Registration is open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician-investigators and research staff from across the country for 2 days of learning and collaboration. The meeting offers colleagues from a variety of research...

gastrointestinal cancer

New NCCN Guidelines®: First to Address Small Intestine Cancers

THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) recently announced the publication of a new set of recommendations focused on cancers in the small intestine. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Bowel Adenocarcinoma are the first treatment guidelines in...

prostate cancer

Looking at Prostate Cancer–Specific Mortality by Gleason Score and Race

Black men suffer disproportionately from prostate cancer, both in terms of incidence and mortality, compared with their white counterparts. However, a newer study conducted by investigators at the University of California, San Francisco, and Dana-Farber Cancer Institute, Boston, found that black...

prostate cancer

Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer

On July 30, 2019, darolutamide was approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.1,2 Approval was based on findings in the double-blind phase III ARAMIS trial (ClinicalTrials.gov identifier NCT02200614), in which 1,509 patients were randomly assigned ...

breast cancer

Tumor Size and Grade Matter, and Ovarian Ablation by Chemotherapy May Explain Subgroup Anomaly in TAILORx

At the 2019 ASCO Annual Meeting, and simultaneously in The New England Journal of Medicine, we heard the third paper reporting results from TAILORx.1,2 The first, in 2015,3 indicated that women with node-negative breast cancers with Oncotype DX recurrence scores less than 11 did extremely well...

Pelotonia Institute for Immuno-Oncology Launched at The Ohio State University Cancer Center

THE OHIO STATE UNIVERSITY Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) announced the formation of the Pelotonia Institute for Immuno-Oncology (PIIO), a comprehensive bench-to-bedside research initiative focused on harnessing...

Dana-Farber Researchers Win Grand Challenge Funding From Cancer Research UK

DANA-FARBER CANCER INSTITUTE researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment, Cancer Research UK announced recently. Dana-Farber Cancer Institute’s Matthew...

breast cancer

Expert Point of View: Carla S. Fisher, MD

CARLA S. FISHER, MD, Medical Director of Breast Surgical Oncology and Associate Professor of Surgery at Indiana University School of Medicine, Indianapolis, commented on the study that sought to identify HER2- positive patients who do, and do not, need surgery after neoadjuvant chemotherapy. “As...

kidney cancer
prostate cancer
immunotherapy

Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer

There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...

breast cancer

Can Some Women With HER2-Positive Breast Cancer Forgo Surgery?

Breast cancer researchers at The University of Texas MD Anderson Cancer Center, Houston, are beginning to select patients with HER2-positive breast cancer who might forgo surgery after neoadjuvant chemotherapy. While this fine-tuning is currently intended to inform clinical trials—in particular, to ...

Advertisement

Advertisement



Advertisement